Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity

Cancer Immunology, Immunotherapy

Volumn 60, Issue 12, 2011, Pages 1763-1774

  Yan, Xiaoli ^a   Zhang, Xiaojun ^a   Wang, Yanzhong ^a   Li, Xinghui ^a   Wang, Saifeng ^a   Zhao, Bao ^a   Li, Yang ^a   Ju, Ying ^a   Chen, Lizhao ^a   Liu, Wenjun ^a   Meng, Songdong ^a  

^a INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

Anti CD25; Antitumor; CTL; gp96; Treg

Indexed keywords

BASILIXIMAB; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GLYCOPROTEIN GP 96;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; EFFECTOR CELL; FEMALE; LOW DRUG DOSE; LYMPH NODE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SPLEEN CELL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION;

ANIMALS; CANCER VACCINES; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 82355185910     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1076-5     Document Type: Article

References (57)

1. PK Srivastava H Udono NE Blachere, et al. 1994 Heat shock proteins transfer peptides during antigen processing and CTL priming Immunogenetics 39 93 98 8276462 10.1007/BF00188611 1:CAS:528:DyaK2cXkvVSguro%3D (Pubitemid 23344809)
2. T Ishii H Udono T Yamano, et al. 1999 Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96 J Immunol 162 1303 1309 9973383 1:CAS:528: DyaK1MXhtVSmurs%3D (Pubitemid 29306999)
3. LE Kropp M Garg RJ Binder 2010 Ovalbumin-derived precursor peptides are transferred sequentially from gp96 and calreticulin to MHC class I in the endoplasmic reticulum J Immunol 184 5619 5627 20410492 10.4049/jimmunol.0902368 1:CAS:528:DC%2BC3cXls1Wjuro%3D
4. PK Srivastava AB DeLeo LJ Old 1986 Tumor rejection antigens of chemically induced sarcomas of inbred mice Proc Natl Acad Sci USA 83 3407 3411 3458189 10.1073/pnas.83.10.3407 1:CAS:528:DyaL28XktVCktr0%3D (Pubitemid 16043046)
5. Y Tamura P Peng K Liu, et al. 1997 Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations Science 278 117 120 9311915 10.1126/science.278.5335.117 1:CAS:528:DyaK2sXmsV2murk%3D (Pubitemid 27446289)
6. NE Blachere Z Li RY Chandawarkar, et al. 1997 Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity J Exp Med 186 1315 1322 9334371 10.1084/jem.186.8.1315 1:CAS:528:DyaK2sXmvVentr4%3D (Pubitemid 27469027)
7. AD Doody JT Kovalchin MA Mihalyo, et al. 2004 Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function J Immunol 172 6087 6092 15128793 1:CAS:528:DC%2BD2cXjs1OjtbY%3D (Pubitemid 38621211)
8. RJ Binder PK Srivastava 2004 Essential role of CD91 in re-presentation of gp96-chaperoned peptides Proc Natl Acad Sci USA 101 6128 6133 15073331 10.1073/pnas.0308180101 1:CAS:528:DC%2BD2cXjsFKnt78%3D (Pubitemid 38520539)
9. T Matsutake T Sawamura PK Srivastava 2010 High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules Cancer Immun 10 7 14 20672796
10. Y Akutsu H Matsubara T Urashima, et al. 2007 Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice Int J Oncol 31 509 515 17671676 1:CAS:528:DC%2BD2sXhtVagurvE
11. T Warger N Hilf G Rechtsteiner, et al. 2006 Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses J Biol Chem 281 22545 22553 16754684 10.1074/jbc.M502900200 1:CAS:528:DC%2BD28XnvVSqu7Y%3D
12. Y Yang B Liu J Dai, et al. 2007 Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages Immunity 26 215 226 17275357 10.1016/j.immuni.2006.12.005 (Pubitemid 46329432)
13. AF McGettrick LA O'Neill 2010 Localisation and trafficking of Toll-like receptors: an important mode of regulation Curr Opin Immunol 22 20 27 20060278 10.1016/j.coi.2009.12.002 1:CAS:528:DC%2BC3cXis1Shsrc%3D
14. AR Jockheck-Clark EV Bowers MB Totonchy, et al. 2010 Re-examination of CD91 function in GRP94 (glycoprotein 96) surface binding, uptake, and peptide cross-presentation J Immunol 185 6819 6830 21048103 10.4049/jimmunol.1000448 1:CAS:528:DC%2BC3cXhsVaqt7jM
15. A Lev P Dimberu SR Das, et al. 2009 Efficient cross-priming of antiviral CD8+ T cells by antigen donor cells is GRP94 independent J Immunol 183 4205 4210 19752220 10.4049/jimmunol.0901828 1:CAS:528:DC%2BD1MXhtFGjs7nJ
16. L Pilla R Patuzzo L Rivoltini, et al. 2006 A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients Cancer Immunol Immunother 55 958 968 16215718 10.1007/s00262-005-0084-8 1:CAS:528:DC%2BD28XjvFGisb4%3D (Pubitemid 43673585)
17. A Testori J Richards E Whitman, et al. 2008 Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group J Clin Oncol 26 955 962 18281670 10.1200/JCO.2007.11.9941 1:CAS:528:DC%2BD1cXjtFelt7s%3D (Pubitemid 351398090)
18. F Belli A Testori L Rivoltini, et al. 2002 Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings J Clin Oncol 20 4169 4180 12377960 10.1200/JCO.2002.09.134 1:CAS:528:DC%2BD38XnsFyqsbg%3D (Pubitemid 35191019)
19. Wood CG, Srivastava P, Lacombe L et al (2009) Survival update from a multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence. J Clin Oncol 27:15s-abstr 3009
20. Parsa A, Crane C, Han S et al (2011) Autologous heat shock protein vaccine (HSPPC-96) for patients with recurrent glioblastoma (GBM): results of a phase II multicenter clinical trial with immunological assessments. J Clin Oncol 29:abstr 2565
21. CG Wood P Mulders 2009 Vitespen: a preclinical and clinical review Future Oncol 5 763 774 19663726 10.2217/fon.09.46 1:CAS:528:DC%2BD1MXpvFyntLo%3D
22. M Aalamian E Fuchs R Gupta, et al. 2006 Autologous renal cell cancer vaccines using heat shock protein-peptide complexes Urol Oncol 24 425 433 16962495 10.1016/j.urolonc.2005.08.009 1:CAS:528:DC%2BD28Xptlyqtrk%3D (Pubitemid 44311549)
23. MR Buckwalter PK Srivastava 2008 "It is the antigen(s), stupid" and other lessons from over a decade of vaccitherapy of human cancer Semin Immunol 20 296 300 18715801 10.1016/j.smim.2008.07.003 1:CAS:528: DC%2BD1cXhtlyhur7M
24. RG Maki PO Livingston JJ Lewis, et al. 2007 A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma Dig Dis Sci 52 1964 1972 17420942 10.1007/s10620-006- 9205-2 1:CAS:528:DC%2BD2sXntVOltb8%3D (Pubitemid 47024649)
25. N Alatrakchi M Koziel 2009 Regulatory T cells and viral liver disease J Viral Hepat 16 223 229 19222744 10.1111/j.1365-2893.2009.01081.x
26. E Elkord EM Alcantar-Orozco SJ Dovedi, et al. 2010 T regulatory cells in cancer: recent advances and therapeutic potential Expert Opin Biol Ther 10 1573 1586 20955112 10.1517/14712598.2010.529126 1:CAS:528:DC%2BC3cXhtlWmtLjE
27. J Shimizu S Yamazaki S Sakaguchi 1999 Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity J Immunol 163 5211 5218 10553041 1:CAS:528:DyaK1MXntlKktbw%3D
28. + regulatory T cells in lymphoid organs J Immunol 183 6330 6337 19841169 10.4049/jimmunol.0900609 1:CAS:528:DC%2BD1MXhtlKhsbbP
29. RY Chandawarkar MS Wagh PK Srivastava 1999 The dual nature of specific immunological activity of tumor-derived gp96 preparations J Exp Med 189 1437 1442 10224283 10.1084/jem.189.9.1437 1:CAS:528:DyaK1MXivFGku7c%3D (Pubitemid 29227529)
30. RY Chandawarkar MS Wagh JT Kovalchin, et al. 2004 Immune modulation with high-dose heat-shock protein gp96: therapy of murine autoimmune diabetes and encephalomyelitis Int Immunol 16 615 624 15039392 10.1093/intimm/dxh063 1:CAS:528:DC%2BD2cXisF2muro%3D (Pubitemid 38489436)
31. H Li M Zhou J Han, et al. 2005 Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments J Immunol 174 195 204 15611241 1:CAS:528:DC%2BD2cXhtFaiurzL (Pubitemid 40007405)
32. J Dai B Liu SM Ngoi, et al. 2007 TLR4 hyperresponsiveness via cell surface expression of heat shock protein gp96 potentiates suppressive function of regulatory T cells J Immunol 178 3219 3225 17312170 1:CAS:528: DC%2BD2sXhvFSitL0%3D (Pubitemid 46333204)
33. Z Liu X Li L Qiu, et al. 2009 Treg suppress CTL responses upon immunization with HSP gp96 Eur J Immunol 39 3110 3120 19839010 10.1002/eji.200939593 1:CAS:528:DC%2BD1MXhsFWhtbbO
34. SD Meng T Gao GF Gao, et al. 2001 HBV-specific peptide associated with heat-shock protein gp96 Lancet 357 528 529 11229675 10.1016/S0140-6736(00)04050- 2 1:CAS:528:DC%2BD3MXhsVKltbw%3D (Pubitemid 32173593)
35. SD Meng J Song Z Rao, et al. 2002 Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides J Immunol Methods 264 29 35 12191506 10.1016/S0022-1759(02)00093-5 1:CAS:528:DC%2BD38XksVahtro%3D (Pubitemid 34615888)
36. AD Cohen DA Schaer C Liu, et al. 2010 Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation PLoS One 5 e10436 e10447 20454651 10.1371/journal.pone.0010436
37. I Jedema NM van der Werff RM Barge, et al. 2004 New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population Blood 103 2677 2682 14630824 10.1182/blood-2003-06-2070 1:CAS:528:DC%2BD2cXjtVaksL8%3D (Pubitemid 38393024)
38. TC Chou P Talalay 1983 Analysis of combined drug effects-a new look at a very old problem Trends Pharmacol Sci 4 450 454 10.1016/0165-6147(83)90490-X 1:CAS:528:DyaL2cXhslWhsA%3D%3D
39. CH Lee YH Chiang SE Chang, et al. 2009 Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses Clin Cancer Res 15 2756 2766 19318495 10.1158/1078-0432.CCR-08-2311 1:CAS:528:DC%2BD1MXksV2nsbY%3D
40. XY Wang H Arnouk X Chen, et al. 2006 Extracellular targeting of endoplasmic reticulum chaperone glucose-regulated protein 170 enhances tumor immunity to a poorly immunogenic melanoma J Immunol 177 1543 1551 16849461 1:CAS:528:DC%2BD28XmvFCmtb0%3D (Pubitemid 44092488)
41. PK Srivastava MR Das 1984 The serologically unique cell surface antigen of Zajdela ascitic hepatoma is also its tumor-associated transplantation antigen Int J Cancer 33 417 422 6698641 10.1002/ijc.2910330321 1:STN:280: DyaL2c7jsVGqtg%3D%3D (Pubitemid 14159040)
42. T Manigold V Racanelli 2007 T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies Lancet Infect Dis 7 804 813 18045563 10.1016/S1473-3099(07)70289-X 1:CAS:528: DC%2BD1cXkvVKrtQ%3D%3D (Pubitemid 350152043)
43. + Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes Eur J Immunol 40 780 786 20039297 10.1002/eji.200939613 1:CAS:528:DC%2BC3cXjtVWku7g%3D
44. C Jacobs P Duewell K Heckelsmiller, et al. 2011 An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma Int J Cancer 128 897 907 20473889 10.1002/ijc.25399 1:CAS:528:DC%2BC3cXhsF2rtrjF
45. MC Whelan G Casey M MacConmara, et al. 2010 Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation Cancer Gene Ther 17 501 511 20186173 10.1038/cgt.2010.8 1:CAS:528:DC%2BC3cXisVCgu7g%3D
46. J Medina-Echeverz J Fioravanti M Zabala, et al. 2011 Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells J Immunol 186 807 815 21148040 10.4049/jimmunol.1001483 1:CAS:528:DC%2BC3MXjs1Ogsw%3D%3D
47. J Mitsui H Nishikawa D Muraoka, et al. 2010 Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals Clin Cancer Res 16 2781 2791 20460483 10.1158/1078-0432.CCR-09-3243 1:CAS:528:DC%2BC3cXlvF2hsr4%3D
48. EJ Akins ML Moore S Tang, et al. 2010 In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice Cancer Res 70 3473 3482 20406970 10.1158/0008-5472.CAN-09-2490 1:CAS:528:DC%2BC3cXltlegu7k%3D
49. M Terabe E Ambrosino S Takaku, et al. 2009 Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody Clin Cancer Res 15 6560 6569 19861451 10.1158/1078-0432.CCR-09-1066 1:CAS:528:DC%2BD1MXhtlCjsrbM
50. AJ Rech RH Vonderheide 2009 Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells Ann N Y Acad Sci 1174 99 106 19769742 10.1111/j.1749-6632. 2009.04939.x 1:CAS:528:DC%2BD1MXhtlehs7vL
51. JF Jacobs CJ Punt WJ Lesterhuis, et al. 2010 Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients Clin Cancer Res 16 5067 5078 20736326 10.1158/1078-0432.CCR-10-1757 1:CAS:528:DC%2BC3cXht1yqsLbF
52. X Li E Kostareli J Suffner, et al. 2010 Efficient Treg depletion induces T-cell infiltration and rejection of large tumors Eur J Immunol 40 3325 3335 21072887 10.1002/eji.201041093 1:CAS:528:DC%2BC3cXhsVOktbnO
53. S Vendetti TS Davidson F Veglia, et al. 2010 Polyclonal Treg cells enhance the activity of a mucosal adjuvant Immunol Cell Biol 88 698 706 20585335 10.1038/icb.2010.76 1:CAS:528:DC%2BC3cXht1GkurvN
54. Van't Land B M Schijf BC van Esch, et al. 2010 Regulatory T-cells have a prominent role in the immune modulated vaccine response by specific oligosaccharides Vaccine 28 5711 5717 10.1016/j.vaccine.2010.06.046
55. NC Di Paolo S Tuve S Ni, et al. 2006 Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses Cancer Res 66 960 969 16424031 10.1158/0008-5472.CAN-05-2388 1:CAS:528:DC%2BD28XlsFyjsw%3D%3D (Pubitemid 43165964)
56. TH Schreiber VV Deyev JD Rosenblatt, et al. 2009 Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination Cancer Res 69 2026 2033 19223534 10.1158/0008-5472.CAN-08-3706 1:CAS:528: DC%2BD1MXisFSrtbc%3D
57. Wang S, Qiu L, Liu G et al (2011) Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice. Vaccine. doi: 10.1016/j.vaccine.2011.1005.1008